These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23109693)

  • 1. Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction.
    Bellavance EC; Alexander HR
    J Clin Oncol; 2012 Dec; 30(35):4290-1. PubMed ID: 23109693
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis.
    Zelek L; Laval G; Asselain B
    J Clin Oncol; 2013 Jul; 31(19):2519-20. PubMed ID: 23733778
    [No Abstract]   [Full Text] [Related]  

  • 3. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
    Mariani P; Blumberg J; Landau A; Lebrun-Jezekova D; Botton E; Beatrix O; Mayeur D; Herve R; Maisonobe P; Chauvenet L
    J Clin Oncol; 2012 Dec; 30(35):4337-43. PubMed ID: 23109694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience.
    Budel M; Martella L; Zambon L; Morson I; Giorda G; Cannizzaro R
    Support Care Cancer; 2021 Feb; 29(2):547-549. PubMed ID: 32914327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Peritoneal mesothelioma: long survival with intraperitoneal chemotherapy, lanreotide and mucolytics].
    Montmayeur G; Thivat E; Gimbergues P; Dib M; Leheurteur M; Curé H; Chollet P; Durando X
    Gastroenterol Clin Biol; 2008 Oct; 32(10):874-5. PubMed ID: 18353584
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide.
    Scherübl H; Wiedenmann B; Riecken EO; Thomas F; Böhme E; Räth U
    Eur J Cancer; 1994; 30A(10):1590-1. PubMed ID: 7833124
    [No Abstract]   [Full Text] [Related]  

  • 7. [Palliative care of bowel obstruction with peritoneal cancer].
    Abadie M
    Rev Infirm; 2013 Oct; (194):38-9. PubMed ID: 24288892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Malignant peritoneal mesothelioma revealed by small bowel obstruction].
    Béchade D; Algayres JP; Baranger B; Arborio M; Louvet C; Krulik M; Bili H; Coutant G; Daly JP
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1237-40. PubMed ID: 11173742
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of lanreotide in an elderly patient with Merkel cell carcinoma.
    Ghidini A; Petrelli F; Fazio I; Santangelo D
    Dermatol Ther; 2020 Jan; 33(1):e13206. PubMed ID: 31886588
    [No Abstract]   [Full Text] [Related]  

  • 10. Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide).
    Kapella M; Gana J; Decroisette E; Aubard Y
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):89-90. PubMed ID: 18684551
    [No Abstract]   [Full Text] [Related]  

  • 11. [Conservative treatment for inoperable malign intestinal obstruction].
    Saarto T; Osterlund P; Lepistö A
    Duodecim; 2013; 129(4):410-7. PubMed ID: 23484358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review.
    Paul Olson TJ; Pinkerton C; Brasel KJ; Schwarze ML
    JAMA Surg; 2014 Apr; 149(4):383-92. PubMed ID: 24477929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
    Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
    J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatic encephalopathy after injection of lanreotide, a somatostatin analog].
    Robin E; Lebrec D; Hammel P; Bernades P; Ruszniewski P
    Gastroenterol Clin Biol; 1996; 20(11):1014-6. PubMed ID: 9119171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for bowel obstruction with peritoneal carcinomatosis.
    Laval G; Marcelin-Benazech B; Guirimand F; Chauvenet L; Copel L; Durand A; Francois E; Gabolde M; Mariani P; Rebischung C; Servois V; Terrebonne E; Arvieux C; ; ; ; ;
    J Pain Symptom Manage; 2014 Jul; 48(1):75-91. PubMed ID: 24798105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An unusual malignant sarcoma of the omentum with extensive intraperitoneal metastases and small bowel obstruction.
    Raafat F
    Ultrastruct Pathol; 1991; 15(3):301-7. PubMed ID: 1871902
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: recommendations for bowel obstruction with peritoneal carcinomatosis by laval et Al.
    Bükki J
    J Pain Symptom Manage; 2014 Nov; 48(5):e5-6. PubMed ID: 25128607
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term treatment of thyrotropin-secreting microadenoma with lanreotide and cabergoline.
    Pichler R; Maschek W
    Eur J Endocrinol; 2001 Feb; 144(2):179-80. PubMed ID: 11182755
    [No Abstract]   [Full Text] [Related]  

  • 19. [Superior mesenteric arterial infusion chemotherapy against intestinal obstruction caused by peritoneal carcinomatosis].
    Ueshima Y; Taniguchi H; Takeuchi K; Oguro A; Tsukuda N; Shioaki Y; Takahashi T; Harada M
    Gan To Kagaku Ryoho; 1991 Aug; 18(11):2012-5. PubMed ID: 1877844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
    Laval G; Rousselot H; Toussaint-Martel S; Mayer F; Terrebonne E; François E; Brixi H; Nguyen T; Bourdeix I; Bisot-Locard S; Zelek L;
    Bull Cancer; 2012 Feb; 99(2):E1-9. PubMed ID: 22265994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.